[Comment] The decade that changed hepatocellular carcinoma: shaping a new treatment paradigm

Abstract

A decade ago, advances in the systemic treatment of advanced hepatocellular carcinoma had been stalled for some time. Sorafenib, the first multikinase inhibitor used to treat advanced hepatocellular carcinoma, had been approved in 2007 based on a modest survival benefit compared with placebo1 and was the sole effective option for more than 10 years. However, over the past decade, systemic therapy for hepatocellular carcinoma has undergone a profound transformation, reshaping clinical practice and leading to unprecedented improvements in patient outcomes.